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1 INTRODUCTION 
1.1 Glioma 
Gliomas are the most common primary brain tumors diagnosed in adults (Stupp et al., 
2005), and account for approximately 77% of the more than 250,000 new cases of 
primary malignant brain tumors identified each year worldwide (Louis et al., 2016). 
In the past, gliomas were categorized based on histological features and graded 
according to histopathological criteria defined by the World Health Organization 
(WHO) (Fuller, 2008). These histologic standards were widely applied to predict 
prognosis and therapeutic benefits for glioma patients. Due to increased research that 
has focused on molecular biomarkers and genetic profiles, the updated 2016 WHO 
classification of tumors of the central nervous system (CNS) now incorporates 
histologic features together with molecular marker information, as shown in Table 1.1 
(Louis et al., 2016; Cancer Genome Atlas Research et al., 2015; Rice et al., 2016; 
Louis, 2016).  
Currently, several molecular markers are recognized as relevant for prognosis and 
decision-making for glioma patients, including the isocitrate dehydrogenase (IDH) 
mutation, 1p/19q co-deletion, H3-K27M mutation, and O6-methylguanin-DNA 
-methyltransferase (MGMT) methylation (Eckel-Passow et al., 2015; Weller et al., 
2015). The new WHO classification system is based on IDH mutation, 1p/19q 
co-deletion, and H3-K27M mutation; whereas MGMT methylation contributes to the 
selection of proper chemotherapy (Olar et al., 2015; Reuss et al., 2015).  
INTRODUCTION 
 2 
 
Table 1.1 Grading of selected CNS tumors according to the 2016 CNS WHO 
 
            Reprinted from (Louis DN, 2016), with permission from the WHO 
The glioblastoma multiforme (GBM), the most common type of malignant glioma, 
has a dismal prognosis, with a median survival of 14 to 16 months (Norden et al., 
2008). Current standard therapies for GBMs include surgical resection followed by 
radiation and chemotherapy with temozolomide (TMZ) (Stupp et al., 2005). Even 
with multimodal therapy, the median overall average survival is only 3 to 9 months 
upon GBM recurrence (Stupp et al., 2009; Yung et al., 2000). A wide range of 
alternative strategies have been investigated or are under evaluation, including 
immunotherapy and gene therapy (Ahluwalia et al., 2011).  
GBMs are highly vascularized brain tumors (Jain et al., 2007). The structures and 
functions of tumor vessels are significantly different from vessels in the normal brain 
(Keunen et al., 2011). Tumor vessels often exhibit a serpentine course, branch 
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irregularly and form arterio-venous shunts (Nagy et al., 2009). Blood flow through 
tumors does not follow a constant, unidirectional path, and vascular density decreases 
during tumor development, leading to ischemia and ultimately necrosis as tumors 
outgrow their blood supply (Gilkes et al., 2014). Previously, anti-angiogenic 
strategies for the treatment of GBMs have been investigated in large clinical studies, 
but treatment of GBMs with bevacizumab (a monoclonal antibody targeting vascular 
endothelial growth factor) has clinically failed (Chinot et al., 2014; Fine, 2014, 
Gilbert et al., 2014). 
1.2 The Function of Pericyte 
Charles Rouget (1873) first described pericytes as “adventitial cells” in the 19th 
century. Zimmermann et al. (1923) later called these cells ‘pericytes’, due to their 
close proximity to endothelial cells (ECs). Pericytes are perivascular cells located in 
the microvessel walls, within the basement membrane (BM) and closely opposed to 
the endothelium (Bergers and Song, 2005). Microscopically, mature pericytes are 
characterized as highly elongated, slender, and branched cells with projections that 
wrap around the vessel wall (Sims, 1986). Pericytes are also characterized by the 
expression of Desmin (Bergers and Song, 2005), platelet-derived growth factor 
receptor β (PDGFR-β) (Winkler et al., 2010), α-smooth muscle actin (αSMA; only in 
large vessels) (Hughes and Chan-Ling, 2004), CD146 (Park et al., 2016), and 
nerve/glial antigen 2 proteoglycan (NG2) (Diaz-Flores et al., 2009; Armulik et al., 
2005). However, these markers are not restricted to pericytes. They are also not 
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always co-expressed, which was previously interpreted to represent varying 
differentiation stages, tissues-specific characteristics, and distinct pathological 
conditions (Schlingemann et al., 1991).  
The number of pericytes and the pericyte coverage of capillaries is much higher in the 
CNS than in the peripheral organs (Armulik et al., 2011). In addition, endothelial cells, 
glial cells, pericytes, and astrocyte end-feet completely cover brain vessels, working 
together to form the “neurovascular unit” (NVU) (El Ali et al., 2014). Pericytes have 
been demonstrated to be an essential component of the NVU, and play an important 
role in both physiological and pathological conditions, as shown in Figure 1.1. (Enge 
et al., 2002; Xian et al., 2006; Nishimura et al., 2016; Paez-Ribes et al., 2009; 
Paquet-Fifield et al., 2009; Sweeney et al., 2016).  
 
Figure 1.1 The function of pericyte in physiological and pathological condition. Under physiological conditions (top row), 
pericytes regulate (1) BBB integrity, i.e., tight or adherens junctions and transcytosis across the BBB; (2) angiogenesis, i.e., 
microvascular remodeling, stability and architecture; (3) phagocytosis, i.e., clearance of toxic metabolites from the CNS; (4) 
CBF and capillary diameter; (5) neuroinflammation, i.e., leukocyte trafficking into the brain; and (6) multipotent stem cell 
activity. Pericyte dysfunction (bottom row) is characterized by (1) BBB breakdown causing leakage of neurotoxic blood-derived 
molecules into the brain (for example, fibrinogen, thrombin, plasminogen, erythrocyte-derived free iron and anti-brain 
antibodies); (2) aberrant angiogenesis; (3) impaired phagocytosis causing CNS accumulation of neurotoxins; (4) CBF 
dysfunction and ischemic capillary obstruction; (5) increased leukocyte trafficking promoting neuroinflammation; and (6) 
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impaired stem cell-like ability to differentiate into neuronal and hematopoietic cells. Pericyte dysfunction is present in numerous 
neurological conditions and can contribute to disease pathogenesis.  
Modified from (Sweeney et al., 2016); Re-print permission from Nature Publishing Group 
Previous studies have shown that pericytes support vessel stability and permeability 
either through direct cell-cell contact, paracrine factors, or through a newly described 
chemo-mechanical signaling pathway (Bexell et al., 2009). Increased expression of 
genes associated with increased vascular permeability (e.g. angiopoietin-2) was 
observed in pericyte-deficient mice (Daneman et al., 2010). Studies have also 
observed decreased pericyte coverage in mice deficient in PDGFR-β or 
platelet-derived growth factor subunit B (PDGF-B), which resulted in increased 
microvascular leakage (Armulik et al., 2005, Leveen et al., 1994, Soriano, 1994). 
Other signaling pathways may also be involved in the interactions between ECs and 
pericytes, including the angiopoietin-1/2 and Tie-2 (Ang/Tie2) and transforming 
growth factor-β (TGF-β) pathways, which are primarily associated with EC viability 
and mural cell differentiation (Birnbaum et al., 2011).  
In addition, pericytes are also involved in controlling the function of the blood brain 
barrier (BBB) by regulating cerebral blood flow and eliminating toxic cellular 
byproducts (Winkler et al., 2009). A study using a viable pericyte-deficient mouse 
model demonstrated that increased permeability occurs through endothelial 
transcytosis (Armulik et al., 2010). The same study also showed that pericytes 
regulate BBB-specific gene expression in endothelial cells and induce polarization of 
the astrocyte end-feet surrounding CNS blood vessels in order to maintain the normal 
function of the BBB (Armulik et al., 2010).  
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Pericytes have been shown to support endothelial cell proliferation and promote 
vessel remodeling and maturation. Initial vascular tubes are formed by proliferating 
immature ECs, which release several signals that induce pericyte recruitment. 
Pericyte coverage is crucial for vessel remodeling and maturation. Recently, a study 
demonstrated that pericytes regulate vessel remodeling via CXCR3-induced 
involution of ECs (Bodnar et al., 2013). The ability of pericytes to induce cord 
dissociation was blocked by inhibition of CXCR3 function in microvascular ECs, and 
thus it is though that pericytes may regulate vascular pruning. In addition, several 
studies have indicated that NG2 expression in pericytes plays an important role in 
pericyte maturation and interactions with ECs (Huang et al., 2010; Ozerdem and 
Stallcup, 2004). 
Some evidence has suggested pericyte as an alternative source of stem/progenitor cell 
within the brain, and have stem cell potential in several pathological disorders 
(Muramatsu and Yamashita, 2014; Diaz-Flores et al., 2009). In the health mouse brain, 
pericytes may originate from multipotent stem cells, mesenchymal stem cells (MSCs) 
in the adult brain, and neuroectoderm-derived neural crest cells in the developing 
brain; several recent reports also indicate that pericytes could originate from bone 
marrow-derived pericyte progenitor cells or glioblastoma stem cells (GSCs) in mouse 
brain with glioma (Ricci-Vitiani et al., 2010; Lamagna and Bergers, 2006; Song et al., 
2005; Bababeygy et al., 2008; Bexell et al., 2009).  
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MSCs are tissue-resident stem cells that can convert to an adipocytes, chondrocytes, 
or osteoblasts lineage (Traktuev et al., 2008; Dellavalle et al., 2007). A range of 
studies have proposed a close relationship between pericytes and MSCs (da Silva 
Meirelles et al., 2006; Crisan et al., 2008). Cultured pericytes have been shown to 
differentiate into osteoblasts (Brighton et al., 1992), chondrocytes (Farrington-Rock et 
al., 2004), and adipocytes (Tang et al., 2008). Besides demonstrating multipotency in 
vitro, pericytes and MSCs share cellular markers. For instance, pericytes express 
characteristic surface markers of MSCs, including CD44, CD73, CD90, and CD105; 
conversely, MSCs express pericyte markers, including PDGFR-β, NG2, Sca-1, and 
α-SMA (Rajantie et al., 2004). In a study conducted by Birnbaum et al. (2011) glioma 
cells induced differentiation of MSCs into pericytes in a mouse model. However, 
recent studies indicate that not all pericytes display similar stem cell potential (Caplan, 
2008, Blocki et al., 2013) and the contribution of pericytes to the pool of MSCs in the 
body was rolled out by a-tracing approach (Guimaraes-Camboa et al., 2017).  
In embryonic development, pericytes of the forebrain and thymus develop from 
neuroectoderm-derived neural crest cells (Bergwerff et al., 1998, Etchevers et al., 
2002), and TGF-β1 signaling drives the differentiation of neural crest-derived 
progenitors into smooth-muscle-like cells (Chen et al., 2004; Darland and D'Amore, 
2001). 
Several studies have shown that bone marrow derived pericyte progenitor cells are 
able to infiltrate brain tumors and mature into pericytes and vascular smooth muscle 
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cells (Du et al., 2008). Du et al. (2008) reported that PDGFR-β+ ScaI+ pericytes, 
which account for 2% of bone marrow-derived cells, infiltrated experimental 
gliomas-an action that depended on expression levels of MMP-9 in CD45+ vascular 
modulatory cells. However, other studies found that bone marrow-derived cells did 
not differentiate into pericytes in intracranial tumors (Paez-Ribes et al., 2009, De 
Palma et al., 2005). In the present study, I will further investigate whether pericytes 
are derived from the bone marrow in the glioma mouse model.  
Recently, Cheng et al. (2013) reported a surprising connection between pericytes and 
brain CSCs in GBMs. The results demonstrated that most pericytes residing in the 
perivascular niche of GBMs originated from CSCs. Another study demonstrated that 
GBM stem cells could differentiate into ECs (Wang et al., 2010). Expression of 
pericyte markers (Desmin, αSMA, and NG2) found to increase upon stimulation with 
glioma-conditioned medium, which was closely associated with the tumor vasculature 
(Bexell et al., 2009). Overall, these findings have revealed that pericytes, through a 
close interaction with CSCs and perivascular cells, participate in tumor initiation and 
progression by acting as tumor promoters (Caspani et al., 2014). 
1.3 The role of pericytes in brain tumor angiogenesis 
Angiogenesis is a multiple-step process involving many molecules and cytokines 
within the tumor microenvironment. Pericytes could secrete growth factors to 
promote EC proliferation and migration, thereby modulating the surrounding 
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extracellular matrix, as shown in Figure 1.2 (Gerhardt and Betsholtz, 2003; Armulik 
et al., 2005; Saunders et al., 2006; Stapor et al., 2014).  
 
Figure 1.2. The role of pericytes in tumor angiogenesis and metastasis. In response to angiogenic stimuli, EC–pericyte 
contacts are disrupted, leading to activated EC and pericyte phenotypes, degradation of the basement membrane, vasodilation, 
and increased vessel permeability. Pericyte investment in the migrating endothelial tip is scarce. EC–pericyte crosstalk via 
several factors known to play critical roles in angiogenesis contribute to matrix degradation, migration, proliferation, and 
endothelial tube formation. Vessel maturation is characterized by pericyte recruitment, functional pericyte investment of the 
endothelium, and assembly of ECM components. Proper EC–pericyte association results in maintenance of vessel integrity. EC–
pericyte dissociation may promote intravasation and extravasation of tumor cells across the disrupted endothelium. Ang, 
angiopoietin; EC, endothelial cell; ECM, extracellular matrix; FGF, fibroblast growth factor; MMPs, matrix metalloproteinases; 
NO, nitric oxide; PDGF, platelet-derived growth factor; S1P, sphingosin-1-phosphate; SDF-1A, stromal derived factor-1A; 
TIMPs, tissue inhibitors of metalloproteinases; VEGF, vascular endothelial growth factor; vSMC, vascular smooth muscle cell. 
Modified from (Sweeney et al., 2016); Re-print permission from John Wiley & Sons publications 
GBMs have a complex tumor microenvironment that contains different stromal cells, 
including ECs, pericytes, and inflammatory cells. Extensive neoangiogenesis and 
tumor infiltration, including recruitment of ECs and pericytes, is considered to be one 
defining characteristic of GBMs (Zuniga et al., 2009). Previous studies have 
demonstrated that high vascularity and overexpression of vascular endothelial growth 
factor (VEGF) and basic fibroblasts growth factor (bFGF) in GBMs contribute 
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significantly to tumor growth and progression and angiogenesis (Fischer et al., 2005; 
Kargiotis et al., 2006; Jain et al., 2007). Several mechanisms of neovascularization 
have been reported for GBMs, including vessel cooption, sprouting of vessels, and 
vasculogenesis (Chao and Hirschi, 2010; Dome et al., 2008). Tumor vessels are 
irregularly shaped, excessively branched, disorganized, leaky, and tortuous (Ruoslahti, 
2002). Within the tumor area, ECs and pericytes show altered functions and 
morphologies compared to their normal counterparts (Hashizume et al., 2000; 
Hellstrom et al., 2001). The BM in tumors is usually discontinuous or absent, and the 
endothelium may also be incomplete or multilayered (Baluk et al., 2003). Hence, 
pericytes in tumors often lack a physical association with ECs.  
Previous studies have demonstrated that pericyte ablation leads to increased vessel 
permeability and poor vessel integrity. These studies have also showed that pericyte 
ablation suppresses tumor growth, promotes tumor invasion, and induces metastatic 
spread (Paez-Ribes et al., 2009; de Groot et al., 2010). Another study used 
NG2-deficient mice to investigate the interaction between pericytes and ECs during 
brain tumor growth and found that tumor volume significantly decreased in 
NG2-deficient mice compared with wild type mice (Huang et al., 2010). However, 
NG2 is not only expressed by pericytes, but also by macrophages, tumor cells, and 
several stromal cell types. Therefore, the NG2 deficiency is not pericyte-specific, and 
other NG2 expressing stromal components within tumor microenvironments may 
contribute to tumor progression. 
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1.4 Study aims 
Pericytes have been shown to play an important role in regulating development and 
maturation of ECs and maintaining function of vessels. Previous studies indicated 
newly generated pericytes may derived from mature pericytes, multipotent stem or 
progenitor cells. In the present study, I applied a lineage-tracing system to follow the 
differentiation of nesting-RFP positive cells. It was discovered nestin-RFP+ cells 
become pericytes during the tumor progression, but initially do not carry pericyte 
markers. A bone marrow chimeric glioma mouse model was used to investigate the 
origination of RFP+ pericytes. In addition, I utilized the cell-lineage ablation glioma 
mouse model to investigate the role of RFP+ cells during glioma progression. 
The aims of this project were: 
(1) Tracing the cell lineage of nestin-RFP expressing cell in a transgenic glioma 
mouse model.  
(2) To investigate the relationship between the RFP expressing cells and vessels; 
(3) To identify the cell types of RFP expressing cells by immunofluorescence 
labelling experiments.  
(4) Investigate if RFP expressing cells derived from the brain or from the bone 
marrow 
(5) To study the role of RFP expressing cells during glioma progression by using the 
cell-lineage ablation glioma mouse model. 
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2 MATERIALS   
2.1 Equipment and devices 
Table 2.1 Equipment and devices 
Equipment/ device Name Provider 
Centrifuges Centrifuge 5415R Eppendorf 
 Universal 30 RF UNIVERSAL 
Fridge(-80°C) Premium LIEBHERR 
Incubator AC-407 Heraeus 
Microliter syringe 1ul micro-syringe Hamilton 
Microscopes Axio Observer A1 Carl Zeiss 
 Axioskop 2 Carl Zeiss 
 Axiovert 135 Carl Zeiss 
 BMS D1-223A Carl Zeiss 
Confocal microscope Broadband TCS SP5 Leica 
Microscope camera AVT HORN SONY 
 AxioCam MRm ZEISS 
Microtome Slide 2003 PFM AG 
Perfusion system Dose IT P910 Integra Biosciences 
pH meter WTW Multical bench Sigma-Aldrich 
Pipette boy Comfort Integra Biosciences 
Pipettes (0-10, 20-200, 100-1000 μl) Eppendorf 
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Shaker Digital Vortex Mixer VWR 
 Sea Star Shaker Biozyme 
Stereotactic Frame  Stoelting 
Sterile hood HERA safe Thermo 
Sutures Ethibond excel (5-0) Ethicon 
Water bath  Memmert 
 
2.2 Chemicals and reagents 
Table 2.2.1 Chemicals and reagents 
Substance Manufacturer Country 
4′,6-Diamidin-2-phenylindol 
(DAPI) 
Sigma - Aldrich St. Louis, USA 
Antibody diluent serum-free with 
background reducing components 
Dako 
Hamburg, 
Germany 
Agarose Sigma - Aldrich St. Louis, USA 
Aqua ad iniectabilia B. Braun 
Melsungen, 
Germany 
Bepanthen® Eye- and Nosecream Bayer 
Leverkusen, 
Germany 
CldU Sigma-Aldrich, Saint Louis, USA 
Cryomatrix Thermo Fisher Waltham, USA 
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Scientific 
Donkey serum Sigma-Aldrich Saint Louis, USA 
Entellan® mounting medium Merck 
Darmstadt, 
Germany 
Eosin G-solution 0.5% Carl Roth 
Karlsruhe, 
Germany 
Ethylenglycol Sigma-Aldrich Saint Louis, USA 
EtOH 100% SAV LP 
Flintsbach, 
Germany 
EtOH 70% SAV LP 
Flintsbach, 
Germany 
EtOH 96% SAV LP 
Flintsbach, 
Germany 
Glycerol Sigma-Aldrich Saint Louis, USA 
Goat serum Sigma-Aldrich Saint Louis, USA 
HCl Sigma-Aldrich Saint Louis, USA 
Hoechst 3342 (1:1000) Life Technologies 
Darmstadt, 
Germany 
IB4 biotinylated (1:100) Vector Laboratories Burlingame, USA 
IB4 FITC (1:200) Sigma-Aldrich Saint Louis, USA 
IdU Sigma-Aldrich Saint Louis, USA 
Ketaminhydrochlorid Pfizer New York, USA 
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(Ketavet, 100 mg/ml) injection 
solution 
Meyer’s Hemalaun Carl Roth GmbH 
Karlsruhe, 
Germany 
Mounting medium for fluorescence 
microscopy 
Ibidi 
Martinsried, 
Germany 
NaCl (Sodium chloride) Roth  
Narcoren (Pentobarbital) Bayer 
Leverkusen, 
Germany 
Na2HPO4 Sigma-Aldrich Saint Louis, USA 
NaH2PO4 Sigma-Aldrich Saint Louis, USA 
PBS 
Apotheke Klinikum 
der Universität 
München 
Munich, Germany 
PFA Sigma-Aldrich Saint Louis, USA 
Protein block Dako Germany 
Hamburg, 
Germany 
Rompun (2%) & Xylazin injection 
solution 
Bayer 
Leverkusen, 
Germany 
Roti® Histol Carl Roth 
Karlsruhe, 
Germany 
Sodium Tetraborate decahydrate Sigma-Aldrich Saint Louis, USA 
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Sucrose Sigma-Aldrich Saint Louis, USA 
Tamoxifen Sigma-Aldrich Saint Louis, USA 
Triton X-100 Roche Diagnostics 
Rotkreuz, 
Switzerland 
Tween-20 Sigma-Aldrich Saint Louis, USA 
 
Table 2.2.2 Commercial kits 
Kit Provider Country 
MaxFluor™ Mouse on Mouse Fluorescence 
Detection Kit (MaxFluor 488) 
Dianova 
Hamburg, 
Germany 
 
2.3 Cell lines  
Table 2.3 Cell lines used in this study 
Cell lines Origin origin     Provider 
GL261 Mouse 
Neurosurgical Research,  
LMU Munich 
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2.4 Mouse strains 
Table 2.4 mouse strain applied in this study 
Strain Provider Country 
Nes-CreERT2+/+;Td-Tomato 
Neurosurgical Research,  
LMU Munich 
Germany 
Nes-CreERT2+/+;Td-Tomato-iDTA 
Neurosurgical Research,  
LMU Munich 
Germany 
PU1-GFP 
Neurosurgical Research,  
LMU Munich 
Germany 
 
2.5 Buffers and solutions 
Table 2.5 Buffers for immunolabeling 
Buffer Containing 
Fixation reagent 
 
4 % Paraformaldehyde 
in 0.1M PB 
Nuclear localization reagent 
100mM Tris, 
0.9% NaCl, 
0.05% Tween 20 
3% Donkey Serum 
In 100ml PBS 
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Washing buffer (TBS) 
 
100 mM Tris 
150 mM NaCl, pH 7.4 
in ddH2O 
30 % Sucrose 
Sucrose (300 g/l) in 0.05 M phosphate 
buffer 
PBT  
Triton-PBS  
 
2.6. Primary antibodies 
Table 2.6 Primary antibodies 
Antibody Origin Dilution Provider Country 
CD146 Rabbit 1:1000 Abcam Cambridge, UK 
CD31 Rat 1:25 
Becton 
Dickinson 
Heidelberg, 
Germany 
BrdU (CldU) Rat 1:250 Abd Serotec Kidlington, UK 
Desmin Rabbit 1:200 Abcam Cambridge, UK 
Iba1 Rabbit 1:500 Wako Pure Neuss, Germany 
Iba1 Goat 1:500 Abcam Cambridge, UK 
BrdU (IdU) Mouse 1:750 
Becton 
Dickinson 
Lakes, USA 
GFP (ChIP grade) Rabbit 1:250 Abcam Cambridge, UK 
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Nestin Rabbit 1:100 Millipore Darmstadt, Germany 
NG2 Rabbit 1:200 Abcam Cambridge, UK 
PDGFR-β Goat 1:50 R+D Systems Minneapolis, USA 
RFP Rabbit 1:200 Abcam Cambridge, UK 
SOX 2 Rabbit 1:200 Abcam Cambridge, UK 
vWF Rabbit 1:400 Dako Hamburg, Germany 
 
2.7. Secondary antibodies 
Table 2.7 Secondary antibodies 
Antibody Origin Dilution Provider Country 
Alexa Fluor 488 Goat 1:250 Dianova 
Hamburg, 
Germany 
Alexa Fluor 488 Rabbit 1:500 Life Technologies 
Carlsbad, CA, 
USA 
Alexa Fluor 594 Rabbit 1:500 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Cy™2 Mouse 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Cy™2 Rat 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Cy™3 Rabbit 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
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Cy™5 Mouse 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Cy™5 Rat 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Biotinylated Rabbit 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Biotinylated Mouse 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Biotinylated Goat 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Biotinylated Rat 1:250 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Alexa Fluor 488 
streptavidin 
- 1:500 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
Alexa Fluor 594 
streptavidin 
- 1:500 
Jackson 
Immuno-Research 
West Grove, PA, 
USA 
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2.8 Software 
Table 2.8 Software products 
Product Supplier 
Image J NIH, Bethesda, MD, USA 
SPSS IBM 
Adobe Microsoft 
GraphPad PRISM 5 GraphPad Software Inc. 
Microsoft office 2011 for mac Microsoft 
Mac OS X Mac 
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3 METHODS 
3.1 Mouse models 
3.1.1 Animal maintenance  
All in vivo experiments were conducted and housed in standardized cages in the 
Walter Brendel Centre for Experimental Medicine, Department of Neurosurgical 
Research, LMU Munich. We performed the animal experiments according to the 
German animal protection act guidelines and were approved by the government of 
Upper Bavaria. The standard water and food were provided available ad libitum. A 
circadian day and night light rhythm of 12 h was maintained.  
3.1.2 Tumor inoculation 
In our brain tumor model, 100.000 GL261 mouse glioma cells per mouse were 
inoculated to the mouse brain and this was defined as day 0 of the experiment. For 
tumor inoculation, mice were anesthetized depending on their individual body weight 
(7uL/g) with anesthetic (0.36 mL 2% Rompun, 1.02 mL 10% Ketavet and 4.86 mL 
0.9% NaCl). After disinfection with 10% potassium iodide solution, the skin of the 
skull was cut with a scalpel blade. Next, we placed the mouse head in the stereotactic 
frame and carefully fixed it in the flat-skull position. Corneas were kept moisturized 
with Bepanthen® eye and nose ointment. A burr hole was made 1.5 mm anterior and 
1.5 mm right of the bregma by drilling with a 23-gauge needle tip. A syringe 
containing 1um of 100,000 GL261 tumor cells was inserted 4 mm deep into the 
mouse brain through the bone hole, and then the needle was retracted to a position of 
3 mm into the brain. The injection was then performed at a rate of 50,000 cells/min. 
After the tumor inoculation, the syringe was carefully taken out over a entire-course 
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of 5 minutes. Finally, the wound was sutured and the animal was returned to its 
habitat.  
3.1.3 Nes-CreERT2+/+;Td-Tomato reporter mouse model 
The Nes-CreERT2+/+;Td-Tomato reporter mouse was applied in vivo studies. Based on 
the Cre (cyclization recombination)/loxP (locus of X over P1) system, a site-specific 
recombinase technology, the selected DNA sequences can be deleted, inserted, or 
inversed. Generally, loxP sites on bacteriophage P1 contain 34 bp DNA sequences, 
including an 8 bp non-palindromic core region and two sets of 13 bp palindromic core 
region (Albanese et al., 2002). Cre recombinase can specifically recombine the loxP 
sites (Lakso et al., 1992), and delete or recombine a DNA sequence of interest, 
(Missirlis et al., 2006).  
In this study, Nes-CreERT2+/+;Td-Tomato mice carrying the Cre transgene under the 
control of the nestin promoter and enhancer located in the second intron of the nestin 
gene were used. Hence, all nestin positive cells also express Cre recombinase 
(Mignone et al., 2004). Nonetheless, in these transgenic mice, Cre recombinase can 
only gain access to the nucleus after Tamoxifen-binding to the ligand binding domain 
of the mutated estrogen receptor α, which is linked to the recombinase. Consequently, 
tamoxifen injection determines the time point of genetic recombination (Feil et al., 
1997).  
In Rosa26-tdTomato mice, a lox-P-site flanked the stop cassette precedes an open 
reading frame encoding red fluorescent protein (RFP) (Soriano, 1999). Thus, if 
NesCreERT2 and Rosa26-tdTomato mice are crossbred generating 
Nes-CreERT2+/+;Td-Tomato mice, Cre recombinase excises the floxed stop cassette of 
the RFP gene after tamoxifen administration (Soriano, 1999). In these mice, all cells 
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that carry the Cre gene sequence will express an RFP signal (i.e., all cells that are 
Nestin positive at the time of tamoxifen administration). As a result, 
Nes-CreERT2+/+;Td-Tomato mice can be used as a fate-mapping model for 
Nestin-positive cells with RFP as the reporter molecule.  
3.1.4 Generation of bone marrow chimeric mice and ip. TAM application 
The bone marrow chimeric mouse model was applied to investigate the origin of 
RFP+ pericyte progenitor cells (Holl, 2013). In this study, two transgenic reporter 
mice models were used as the donor mice, including Nes-CreERT2+/+;Td-Tomato and 
PU1-GFP donor mice. PU1 is a transcriptional activator that is expressed by mature 
myeloid and lymphoid lineage cells (DeKoter and Singh, 2000, Chen et al., 1995). 
PU1-GFP mice are suitable to observe cells of myeloid lineage as described 
previously (Back et al., 2004). Bone marrow-derived cells were harvested from tibiae 
and femurs of 6 ~ 8-week donor mice. The BM cells (5 x 106), including PU1-GFP 
and Nes-Cre-RFP cells, were transferred to lethally irradiated (split dose: 600 rad at 
day -1) recipient WT_ C57BL/6 and Nes-CreERT2+/+;Td-Tomato mice by intravenous 
(IV) injection. After BM transfer, the mice received an antibiotic treatment for one 
month (tetracycline 0.1g/L, drinking water). Successful reconstitution was defined as > 
94% engraftment of blood GFP+/RFP+ cells by FACS analysis. The TAM injection 
was performed at days 4 to 6 after the tumor inoculation. 
3.1.5 Nes-CreERT2+/+;Td-Tomato with loxP-conditional diphtheria toxin A (iDTA) 
mouse model 
The genetic cell lineage ablation mouse model of Nes-CreERT2+/+;Td-Tomato-iDTA 
(tamoxifen-inducible diphtheria toxin expression) was generated by crossing 
Nes-CreERT2+/+;Td-Tomato mice with ROSA-iDTA transgenetic mice 
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(Brockschnieder et al., 2006). When we injected TAM, the ROSA-26Sor promoter 
could induce the expression of diphtheria toxin (DT) in the Nes-cre-expressing cells 
(RFP+ cells). This mouse model allows ablation of Cre recombined RFP+ cells, 
namely the Nes-iDTA group. Nes-CreERT2+/+;Td-Tomato mice were crossed with 
ROSA-iDTA wild type mice were applied as the control group, namely the Nes-RFP 
group.  
3.2 Group design of different mouse models and treatment procedure 
In cell lineage-tracing experiments, male and female Nes-CreERT2+/+;Td-Tomato 
transgenic mice were divided into three groups, including the Nes-7 days, the Nes-14 
days, and the Nes-21 days group. The GL261 tumor cells were inoculated on day 0 
followed by the TAM administration on day 1 to day 3 in the Nes-7 days group, on 
day 4 to day 6 in the Nes-14 days group and the Nes-21 days group. Mice were 
sacrifice at 7, 14, 21 days after tumor inoculation in the Nes-7, the Nes-14, and the 
Nes-21 days groups, respectively (Figure 3.1-A). As controls, three further groups 
were included in this experiment, as shown in Figure 3.1-B. They were genetically 
modified and treated in the same manner as the experimental groups with the 
following modificatious conditions: mice of the Control 1 group did not carry the 
NesCreERT2 transgene; the Control 2 group did not receive tamoxifen treatment; the 
Control 3 group was not inoculated with GL261 tumor cells but stabbed with the 
injection needle (stab-wound control). Table 1 shows the detail for all experimental 
mice. 
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Figure 3.1 Treatment scheme for cell lineage-tracing experiments  
 
Table 3.1 Characteristics of different groups in this study 
Group name Mouse model Number 
Sacrifice 
date after 
tumor 
inoculation 
Nes-7 days Nes-CreERT2+/+;Td-Tomato 6 7 
Nes-14 days Nes-CreERT2+/+;Td-Tomato 8 14 
Nes-21 days Nes-CreERT2+/+;Td-Tomato 8 21 
Nes-18 days Nes-CreERT2+/+;Td-Tomato 3 18 
Nes-P90 Nes-CreERT2+/+;Td-Tomato 4 14 
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Nes-P360 Nes-CreERT2+/+;Td-Tomato 4 14 
Control 1 Nes-CreERT2wt;Td-Tomato 3 14 
Control 2 Nes-CreERT2+/+;Td-Tomato 3 14 
Control 3 Nes-CreERT2+/+;Td-Tomato 3 14 
BM/Nes-Td-Tomato 
Recipient: C57BL/6 
Donor: Nes-CreERT2+/+;Td-Tomato 
2 14 
BM/PU1-GFP 
Recipient: Nes-CreERT2+/+;Td-Tomato 
Donor: PU1-GFP 
4 14 
Nes-iDTA Nes-CreERT2+/+;Td-Tomato -iDTA 6 14 
Nes-RFP Nes-CreERT2+/+;Td-Tomato -iDTAwt 5 14 
 
To investigate if recombined cells would only be generated in the early stage of tumor 
growth or also later in tumor progression, we designed another experimental group in 
which Cre recombinase was activated by TAM treatment on 12 to 14 days after tumor 
cells injection, namely Nes-18 days group. In this experiment, we compared 
recombined cells between the Nes-7 days group and the Nes-18 days group. (Figure 
3.2).  
 Figure 3.2 Treatment scheme and procedures for the experiment to investigate recombined cells between 
the early- and the later-stage during tumor progression  
To investigate whether age influenced the number of RFP expression cells during 
tumor progression. Nes-CreERT2+/+;Td-Tomato mice, in which received tumor 
inoculation at postnatal day 90, were used as the Nes-P90 group to investigate the 
Nes-7 days group
GL261
Inoculation TAM ip. Sacriﬁce
Nes-18 days group
Sacriﬁce
GL261
Inoculation TAM ip.
Day 0 Day 1 Day 3 Day 7
Day 0 Day 12 Day 14 Day 18
Cre recombinase was activated
in the early stage of tumor growth
Cre recombinase was activated
in the later stage of tumor growth
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RFP expression in young mouse brain. For aging mice, Nes-CreERT2+/+;Td-Tomato 
mice were inoculated with tumor cells at postnatal day 360, namely the Nes-P360 group. 
Then, the treatment scheme was same as the procedure for the Nes-14 days group 
(Figure 3.3) 
Figure 3.3 Treatment scheme and procedures for the experiment to investigate the number of RFP 
expression cells recombined cells between the young and the aging mouse brain during tumor progression  
In the bone marrow chimeric experiments, C57B1/6 wild type mice were transplanted 
with the Nes-Cre-RFP donor cells from Nes-CreERT2+/+;Td-Tomato transgenic mice 
after lethal irradiation, namely the BM/Nes-Td-Tomato group. For the positive control 
group, Nes-CreERT2+/+;Td-Tomato transgenic mice were transplanted with PU1-GFP 
donor cells after lethal irradiation, namely the BM/PU1-GFP group (Fig. 3.4). After 
one month of antibiosis, I orthotopically inoculated the Gl261 cells and then animals 
were treated as outline for Nes-14 days group (Fig. 3.1-A). 
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Figure 3.4 Treatment scheme and pocedures for bone marrow chimeric experiments.  
For cell lineage depletion experiment, two groups were designed including the 
Nes-iDTA group (with cell-lineage ablation) and the Nes-RFP control group (without 
cell-lineage ablation). GL261 tumor cells were inoculated on day 0 followed by the 
TAM administration on day 4 to day 6. Mice were sacrificed at 14 days after tumor 
inoculation, as shown in Figure 3.5. 
 Figure 3.5 Treatment scheme and procedures for cell lineage depletion experiment.  
The BM/PU1-GFP group The BM/Nes-Td-Tomato group
Recipent: Nes-CreERT2+/+;Td-Tomato mice Recipent: C57B1/6 mice
Recieve Lethal Irradiation 1 x 10 Gy
Recieve Antibiotics Treatment for One Month (Tetracycline 0.1g/L)
Tumor Inoculation (GL261, 100,000 cells)
TAM Injection at Day 4 - Day 6 After the tumor inoculation 
Sacriﬁce at Day 14 After the tumor inoculation 
Transplanted with PU1-GFP cells
From PU1-GFP donor mice
(5,000,000 cells)
Transplanted with Nes-Cre-RFP cells
From Nes-CreERT2+/+;Td-Tomato donor mice
(5,000,000 cells)
Nes-iDTA group
Nes-RFP group
Nes-CreERT2;Td-Tomato with 
cell-lineage ablation
Nes-CreERT2;Td-Tomato without 
cell-lineage ablation
Sacriﬁce
GL261
Inoculation TAM ip.
Day 0 Day 4 Day 5Day 6 Day 14
Sacriﬁce
GL261
Inoculation TAM ip.
Day 0 Day 4 Day 5Day 6 Day 14
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3.3 Induction of Cre recombinase by tamoxifen injection 
Based on the treatment protocol, 75 mg tamoxifen/kg body weight of the animal 
(dissolved in corn oil) was administered. The injections were performed 
intraperitoneally once in 3 continuous days. Mice of control 2 group only received a 
corn oil injection.  
3.4 Histology 
3.4.1 Perfusion and tissue preparation 
Mice were killed at 7, 14, 18, and 21 days after glioma cells inoculation and perfused 
with phosphate buffered saline (PBS) followed by 4% paraformaldehyde (PFA) (Gage 
et al., 2012). After successful perfusion, the brain parenchyma was dissected and kept 
in a 4% PFA solution for 2 days at 4°C in order to postfix the tissue. Afterwards, the 
specimens were dehydrated in a 30% sucrose solution diluted in PBS. Then, brains 
were frozen in Cryomatrix for at least 1 day at −20°C. As the tissue was then prepared 
for cutting, 40-μm horizontal sections were made and preserved as free-floating 
sections in a 24-well-plate filled with cryoprotectant (ethylenglycol, glycerol and 0.1 
M PO4 buffer in a 1:1:2 solution at pH 7.4), which protects the tissue from freezing. 
The whole well plate was kept at −20°C protected from light by aluminium foil.  
3.4.2 H&E staining 
Hematoxylin-eosin staining (H&E staining) includes the application of the basic dye 
hematoxylin, which colors acid structures blue, and an alcohol-based acidic Eosin, 
which colors base structures bright pink (Feldman and Wolfe, 2014). This staining 
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was conducted as follows in order to estimate the individual tumor volume of the 
mice in the various groups:   
a) Mounting of the sections 
b) Dehydration in 100% Ethanol for 30 sec 
c) Staining in Meyer’s Hemalaun solution for 5 min 
d) Rinsing in running tap water for 5 min 
e) Counter staining with 0.5% Eosin G-solution for 10 sec 
f) Dipping very shortly in a. dest. (Caution: Eosin is water soluble) 
g) Dehydration through ascending alcohol series starting with 70% EtOH for 20 sec 
h) Continued by 96% EtOH for 1 min 
i) Continued by 100% EtOH for 1 min 
j) Continued by Roti®-Histol for 1 min 
k) Repetition of the last step with fresh Roti®-Histol 
l) Covering with mounting medium  
3.5 Immunohistochemistry 
Immunohistochemistry was performed by the direct, indirect, or labeled 
streptavidin-biotin (LSAB method) using fluorescence techniques (Chen et al., 2010, 
Furukawa et al., 2017, Ramos-Vara, 2005). However, all of them rely on the same 
principle of an antibody specifically detecting its respective antigen in the mouse 
tissue. All stains were performed as free-floating sections, which lead to improved 
antibody penetration. Sections were washed in PBST (PBS with 0.1% Tween-20) 3 × 
5 min at room temperature and then incubated with blocking solution (5% normal 
donkey serum in PBS, with 0.3% Triton-X100) for 1 h at room temperature (RT). The 
free-floating sections were incubated at 4°C or RT overnight with primary antibodies 
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diluted in 3% normal donkey serum. After washing by PBT, antibody staining was 
revealed using species-specific fluorophore-conjugated (Cy3, Cy5, Cy2 from Jackson, 
Alexa 488, Alexa 594 from molecular probes) or biotin-conjugated secondary 
antibodies (Invitrogen), which then react with fluorescent-dye labeled Streptavidin 
(Alexa 488, Alexa 594 with con-streptavidin, Cy5 with con-streptavidin). DAPI 
(1 μg/mL, Sigma) was used for counterstaining. The sections of control were stained 
with secondary antibody alone. The Immunohistochemistry was used for vWF, 
Desmin, PDGFR-β, SOX2, NG2 and CD146 stains.  
3.5.1 Stain with Mouse-on-Mouse kit 
Staining with anti-mouse antibody on mouse tissue can present a challenge. As 
secondary antibodies may also detect endogenous mouse IgG in inflamed tissue in 
tumors. As the blood-brain-barrier is opened, due to tumor progression in glioma 
mouse models, the immunoglobulin can directly penetrate to the tumor and is then 
detected by the secondary antibody. In order to reduce this background staining, a 
Dianova MaxFluor™ Mouse-on-Mouse Fluorescence Detection Kit was utilized 
(Goodpaster and Randolph-Habecker, 2014). The procedure was conducted as 
follows:  
a) Washing in PBST (PBS, 0.1% Tween-20) 2 x 5 min at room temperature 
b) Washing in H2O 2 x 5 min at room temperature 
c) Denaturation in 2 M HCl for 45 min at room temperature 
d) Neutralization with 0.1 M sodium tetraborate for 15 min at room temperature 
e) Washing in PBST (PBS, 0.1% Tween-20) 6 x 10 min at room temperature 
f) Mounting and circleing the sections with a Dako pen (a fat pen which ensures 
that the different solutions remain on the section) 
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g) Fixation on the microscope slide with 4% PFA for 10 min 
h) Washing in PBST (PBS, 0.1% Tween-20) 3 x 2 min at room temperature 
i) Blocking with Protein blocking solution (reagent 1) for 10 min at room 
temperature 
j) Blocking with MaxMOM blocking reagent (reagent 2) for 1 h at room 
temperature 
k) Primary antibody (see table for dilutions) diluted in PBS, 0.3% Triton X-100, 5% 
serum of the secondary antibody’s host species over night at 4 °C 
l) Washing in PBST (PBS, 0.1% Tween-20) 3 x 2 min at room temperature 
m) Fluorescence signal enhancer (reagent 3) for 30 min at room temperature 
n) Washing in PBST (PBS, 0.1% Tween-20) 3 x 2 min at room temperature 
o) Max Fluor labeled linker (reagent 4) 1:200 and secondary antibody (see table for 
dilutions) diluted in Fluorescent Diluent (reagent 5) for 2 h at room temperature 
p) Washing in PBST (PBS, 0.1% Tween-20) 3 x 2 min at room temperature 
q) Rinsing shortly in distilled water 
r) Alexa Hoechst 1:1000 for 1 min at room temperature as a nuclear stain 
s) Covering with fluorescence mounting medium 
3.6 Microscopy 
In this study, light, fluorescence and confocal microscopies were conducted. Light 
microscopy was only applied for the evaluation of H&E stains using a Zeiss Axioskop 
2 light microscope and a Breukoven BMS D1-223A light microscope. For 
quantification of fluorescent structures, fluorescence microscopy and confocal 
microscopy were conducted. Unlike conventional wide-field microscopes, confocal 
microscopy was applied to control depth of field, and reduce of background 
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information; also, optical sections from thick tissues can be collected. This was 
performed to obtain high-resolution imaging. Image series were viewed as both a 
maximal projection of all plains and as a single plain at a chosen z-position.  
3.7 Evaluation criteria 
For immunohistochemical staining, the extent of colocalization of the traced cells 
with a variety of markers was evaluated according to the following criteria: As the 
reporter molecule (RFP) is expressed in the cytoplasm, markers that are present in the 
same compartment (Desmin) were interpreted as colocalized if both fluorophores 
were clearly identifiable in the cytoplasm of the same cell. If the used marker, 
however, is expressed in other compartments as the nucleus (SOX2) or the cell 
surface (NG2, PDGFR-β, VWF), cells were interpreted as colocalized if RFP-positive 
cell contained a stained nucleus. Cells were interpreted as perivascular if they were 
located at maximum 1 μm to a vWF positive vascular structure.  
For all quantifications, a 20× and a 100×magnification were used. Quantifications 
were conducted from four randomly selected optical fields in the tumor, the 
peritumoral (optical field surrounding the tumor), and the contralateral (optical field 
of a corresponding region in the contralateral, tumor-free hemisphere) regions per 
section. Four sections from corresponding brain regions were taken per animal, a total 
of 48 optical fields per animal were evaluated for every immunohistochemical stain. 
All quantifications were performed from a picture of the respective optical field. The 
counting was performed by hand with the support of Image J software.   
Confocal image analyses were performed using the maximal projection and crosshair 
mode of Leica LAS AF imaging software. Only if pixels colocalized in the three 
directions (xy-, xz- and yz- plane) were the cells regarded as double/triple positive.  
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3.8 Statistical analysis 
The acquired data were analyzed by the GraphPad Prism software (version 5.04). The 
unpaired Student’s t-test was applied to compare quantified data between experiment 
and control groups; each experiment was performed at least three times. I applied 
1-way analysis of variance to analyze the quantification results of the tumor area, the 
peritumoral area, and the contralateral side. Statistical significance is assumed if P ≤ 
0.05. 
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4 RESULTS 
4.1 RFP expression in the Nes-CreERT2+/+;Td-Tomato glioma mouse model 
4.1.1. Localization and characterization of RFP positive cells 
In order to investigate the localization of nestin-RFP+ cells in our glioma mouse 
model, I analyzed tumor, peritumoral, contralateral, subventricular zone (SVZ), and 
olfactory bulb (OB) in Nes-CreERT2+/+;Td-Tomato mice. I found the most RFP+ cells 
in the tumor (Fig. 4.1.1-a), SVZ (Fig. 4.1.1-b), and OB (Fig. 4.1.1-d); while few cells 
were found in the peritumoral area (Fig. 4.1.1-c) and the contralateral tumor-free 
brain hemisphere (Fig. 4.1.1-e). Furthermore, I found that RFP+ cells present a 
vessel-like morphology at 21 days after tumor inoculation, as shown in Fig. 4.1.1-f. 
Therefore, we analyzed the RFP expression by co-staining with VWF (see Fig. 4.2) 
 
Figure 4.1.1: Localization and characterization of RFP expressing cells in the Nes-CreERT2+/+; Td-Tomato 
glioma mouse model at 21 days after tumor cells inoculation. Fluorescence images show RFP expressing cells 
in the tumor (a), SVZ (b), peritumoral (c), OB (d), and contralateral tumor-free brain hemisphere (e) in 
Nes-CreERT2+/+;Td-Tomato mice at 21 days after tumor cells inoculation (20x). In addition, f showed the 
morphology of RFP+ cells like vessel structures (63x). Scale bars are 200 μm in 20x pictures, and 50 μm in 63x 
pictures. 
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RESULTS 
 37 
 
4.1.2. Tracing RFP+ cells in the Nes-CreERT2+/+;Td-Tomato glioma mouse model 
during glioma progression  
During tumor progression, the number of RFP+ cells significantly increased in the 
Nes-21 days group as compared with the Nes-7 days group in the tumor area, the 
peritumoral area, and the contralateral area (Fig. 4.1.2-A). In the tumor area, the 
number of RFP+ cells was 13.58 ± 2.62 in the Nes-7 days group, and the number 
increased to 21.55 ± 3.45 in the Nes-14 days group and 31.05 ± 3.47 in the Nes-21 
days group (p < 0.0001, Fig. 4.1.2-B). In the peritumoral and the contralateral area, 
the number of RFP+ cells increased from 7.81 ± 2.9 and 4.27 ± 1.38 in the Nes-7 days 
group to 11.31 ± 2.54 and 6.21 ± 2.75 in the Nes-21 days group, respectively. 
 
Figure 4.1.2 The number of RFP+ cells increased in Nes-CreERT2+/+;Td-Tomato mice during glioma 
progression. A) The RFP+ (red) expression significantly increased from 7 days to 21 days after tumor inoculation 
within the tumor, the peritumoral, and contralateral tumor-free brain hemisphere. B) Quantification of the number 
of RFP+ cells (n = 12 random fields per mouse): the amount of RFP positive cells significantly increased from 7 to 
21 days, especially in the tumor (p<0.0001) but also in the peritumoral (p < 0.05) and the contralateral area (p < 
0.05). Data are represented as mean ± SEM. Scale bar is 200 μm (*p < 0.05, ****p < 0.0001, nsno significant).  
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4.1.3 RFP positive cells are continuously generated during tumor development  
In order to investigate if recombined cells are generated in the early stage of tumor 
growth or are also generated later in tumor progression, I compared RFP expression 
between the Nes-7 days group and the Nes-18 days group (Fig. 3.2; Table 3.1). The 
results showed no difference in the number of RFP expressing cells between the 
Nes-7 days group and the Nes-18 days group in the tumor, peritumoral, and 
contralateral tumor-free brain hemispheres (Fig. 4.1.3). Thus, my results showed that 
the Cre recombined cells are continuously generated during tumor development. 
 
Figure 4.1.3 The number of RFP expressing cells between the Nes-7 days group and the Nes-18 days group. 
(A) Representative images showed the number of RFP expression was similar between two groups. (B) 
Quantification of the number of cre recombined RFP+ cells (n = 12 random fields per mouse) showed no 
significant difference between the Nes-7 days group and the Nes-18 days group in the tumor, the peritumoral, and 
the contralateral area. Data are represented as mean ± SEM (ns no significant). Scale bar is 200 μm. 
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4.1.4 The number of RFP expressing cells decreased in aging mouse brain as 
compared with young mice  
Several previous studies suggested that the regeneration capacity of neural stem cells 
is reduced in the aging brain. To investigate whether age influences the number of 
RFP expression cells during tumor progression, I compared the RFP expression 
between the Nes-P90 group (age at operation was 90 day) and the Nes-P360 group 
(age at operation was 360 day) (Fig. 3.3; Table 3.1) at 14 days after tumor cells 
inoculation. As compared with the Nes-P360 group, the number of RFP+ cells was 
significantly higher in the Nes-P90 group in the tumor area (21.55 ± 3.45 young 
versus 17.06 ± 2.93, aged; P = 0.0005), the peritumoral area (8.57 ± 2.29 young 
versus 2.45±2.10 aged; P < 0.0001), and the tumor-free brain hemisphere (4.12 ± 1.45 
young versus 1.90 ± 1.44 aged; P = 0.0063), (Fig. 4.1.4). These results indicate that 
RFP positive cells have a somewhat reduced capacity to generate new progeny with 
advanced age, but the ability to generate new pericytes in the older brain is 
maintained. This is in state contrast to the capacity for adult neurogenesis, which 
declines much more in the old brain.   
 
Figure 4.1.4 Quantifications of the number of RFP+ cells between the Nes-P90 group and the Nes-P360 
group. There are 4 mice in the Nes-P90 group (age at operation was 90 day) and 4 mice in the Nes-P360 group 
(age at operation was 360 day). The number of RFP+ cells (n = 12 random fields per mouse) was decreased in the 
Nes-P360 group as compared with the Nes-P90 group within the tumor (p < 0.005), peritumoral (p < 0.001), and 
contralateral areas (p < 0.01). Data are represented as mean ± SEM (**p < 0.01, ***p < 0.005, **** p < 0.0001). 
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4.2 RFP+ cells form close associations with vWF+ cells  
Then we assessed the relationship between RFP+ and vascular cells by 
immunofluorescence staining with an antibody directed against vWF. The results 
showed that RFP+ cells localized near vWF+ endothelial cells in the tumor area. 
Morphologically, RFP+ cells extended long cell processes across the surface of 
endothelial cells (Fig. 4.2.1.) 
 
Figure 4.2.1 Confocal microscopy for intratumoral RFP+ cells and immunofluorescence labelling of von 
Willebrand Factor (vWF) in the Nes-7 days group and the Nes-21 days group. Confocal microscopy showing 
RFP+ cells in the tumor-core and immunofluorescence labeling for the endothelial cell-marker vWF in the 
Nes-CreERT2+/+;Td-Tomato glioma mouse model at 7 days and 21 days after tumor inoculation; note that RFP+ 
cells do not colocalize with vWF, suggesting the perivascular localization of RFP+ cells. Scale bars are 50 μm in 
overview-pictures, and 20 μm in orthogonal view (crosshairs). 
The number of RFP+ located next to vWF+ cells significantly increased with tumor 
progression from 4.53 ± 1.31 in the Nes-7 days group to 28.57 ± 2.37 in the Nes-21 
days group (Fig. 4.2.2-A). Seven days after tumor inoculation, only a small portion of 
RFP+ cells localized near vWF+ cells in the tumor area (21.62%). The proportion of 
RFP+ cells located next to vWF+ cells accounting for all RFP+ cells was quantified 
as 82.86% in the Nes-14 days group and as 92.23% in the Nes-21 days group (Fig. 
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4.2.2-B). The percentage of RFP+ cells located next to vWF+ cells accounting for all 
VWF+ cells was 15.14% in the Nes-7 days group; then that increased to 48.55% in 
the Nes-21 days group (Fig. 4.2.2-C). 
 
Figure 4.2.2 Quantification of intratumoral RFP and VWF expressing cells in Nes-CreERT2+/+;Td-Tomato 
glioma mice at the 7 days, 14 days, and 21 days after tumor inoculation. A) Quantification of RFP+, vWF+, 
and RFP+ cells located next to vWF+ cells (n = 12 random fields per mouse) in the tumor area in the Nes-7 (n = 6), 
Nes-14 (n = 8), and Nes-21 days (n = 8) groups. The percentage of RFP+ cells located next to vWF+ cells 
accounting for all RFP+ cells (B) and all VWF+ cells (C) were compared between three experimental groups. Data 
are represented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001). 
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4.3 Observing the pericyte-lineage in a glioma mouse model during tumor 
progression 
4.3.1 RFP+ cells differentiated into pericytes expressing Desmin  
After I confirmed that the RFP+ cells become perivascular cells over the course of 
tumor growth, we applied several pericyte markers to identify the cell-lineage 
relationship of these RFP+ cells. First, I performed Desmin staining to label pericytes. 
In the tumor area, RFP+ cells, Desmin+ cells, and RFP/Desmin double+ cells are 
abundantly increased during tumor progression from 7 days to 21 days after tumor 
inoculation. At a later stage of tumor development, RFP+ cells mostly express a 
marker for mature pericytes (Desmin). The highest number of RFP/Desmin double 
positive cells was observed in the Nes-21 days group (22.26 ± 3.05), which is 
significantly different from double positive cells in the Nes-7 days group (3.15 ± 0.66, 
p < 0.0001) and the Nes-14 days group (9.44 ± 2.62, p < 0.0001) (Fig. 4.3.1.1-A). The 
percentage of RFP/Desmin double positive cells among all RFP+ cells was 23.23% in 
the Nes-7 days group; then that increased to 71.98% in the Nes-21 days group (p < 
0.0001, Fig. 4.3.1.1-B). The percentage of RFP+/Desmin double positive cells among 
all Desmin+ cells significantly increased to 33.44% in the Nes-21 days group as 
compared with 7.47% in the Nes-7 days group (Fig. 4.3.1.1-C).  
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Figure 4.3.1.1 Quantification of the number of RFP+, Desmin+, and RFP/Desmin double positive cells in the 
tumor area of Nes-CreERT2+/+;Td-Tomato glioma mice. A) The number of RFP+, Desmin+, and RFP/Desmin 
double+ cells in the Nes-7 (n = 6), Nes-14 (n = 8), and Nes-21 days groups (n = 8). The percentage of double+ 
cells accounting for all RFP+ cells (B) and all Desmin+ cells (C) were compared between three experimental 
groups. Data are represented as mean ± SEM (**p < 0.01, ****p < 0.0001). 
Confocal microscopy demonstrated that RPF+ cells co-localized with 
immunofluorescence labeling for Desmin+ cells. Most RFP+ cells did not express 
Desmin in the Nes-7 days group; however, the majority of RFP+ cells co-localized 
with Desmin+ cells in the Nes-21 days group, indicating the RFP+ cells differentiated 
into mature pericytes during tumor progression. (Fig. 4.3.1.2).  
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Figure 4.3.1.2 Immunofluorescence labelling for Desmin to investigate if RFP+ cells are pericytes. Confocal 
fluorescence images showed the expression of RFP (red) and Desmin (green) in the tumor area between the Nes-7 
days group and the Nes-21 days group. Scale bars are 50 μm in overview-pictures, and 20 μm in orthogonal view 
(crosshairs). 
Furthermore, we observed that RFP+ cells expressing Desmin were located close to 
blood vessels. The number of double positive (RFP+, Desmin+) cells located close to 
blood vessels significantly increased from 2.38 ± 0.83 in the Nes-7 days group to 
20.88 ± 3.27 in the Nes-21 days group (p < 0.00001, Fig. 4.3.1.2). The percentage of 
RFP/Desmin double+ cells located close to blood vessels accounting for all double+ 
cells was 66.6% in the Nes-7 days group and 93.61% in the Nes-21 days group. These 
results confirmed that RFP+ cells expressing Desmin are mature pericytes. 
 
Figure 4.3.1.3 Quantification of the RFP/Desmin double positive located close to vessel cells in glioma. A) 
the number of RFP/Desmin double+ cells located close to vessel cells (n = 12 random fields in the tumor area); 
B) the proportion of RFP/Desmin double+ cells to vessel cells accounting for all double+ cells. Data are 
represented as mean ± SEM **** p < 0.0001). 
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In the peritumoral area, the number of single RFP+ and RFP/Desmin double positive 
cells only marginally increased in the Nes-21 days group as compared to those in the 
Nes-7 days group (Fig. 4.3.1.4-A). No difference was observed in the percentage of 
RFP/Desmin double+ cells accounting for all RFP+ cells (Fig. 4.3.1.4-B) or all 
Desmin+ cells (Fig. 4.3.1.4-C) between the Nes-7, Nes14, and Nes-21 days groups.  
 
Figure 4.3.1.4 Quantification of the number of RFP+, Desmin+, and RFP/Desmin double positive cells in the 
peritumoral area of Nes-CreERT2+/+;Td-Tomato glioma mice. A) The number of RFP+, Desmin+, and 
RFP/Desmin double+ cells in the Nes-7 (n = 6), Nes-14 (n = 8), and Nes-21 days groups (n = 8). The percentage 
of double+ cells accounting for all RFP+ cells (B) and all Desmin+ cells (C) between three experiment groups. 
Data are represented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, ns no significant). 
In the contralateral hemisphere, no differences were observed in the number of RFP+, 
Desmin+, and RFP/Desmin double positive cells, and the percentage of RFP/Desmin 
double positive cells among all RFP+ or all Desmin+ cells between Nes-7, Nes-14, 
and Nes-21 days groups remained constant over time (Fig. 4.3.1.5). 
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Figure 4.3.1.5 Quantification of the number of RFP+, Desmin+, and RFP/Desmin double positive cells in the 
contralateral tumor-free brain hemisphere of Nes-CreERT2+/+;Td-Tomato glioma mice. A) The number of 
RFP+, Desmin+, and RFP/Desmin double+ cells in Nes-7 (n = 6), Nes-14 (n = 8), and Nes-21 days groups(n = 8). 
The percentage of double+ cells accounting for all RFP+ cells (B) and all Desmin+ cells (C) between three 
experimental groups. Data are represented as mean ± SEM (ns no significant). 
 
4.3.2 Differentiated RFP+ cells expressing PDGFR-β during the tumor 
progression 
Immunostaining for PDGFR-β, another frequently used pericytes marker (Winkler et 
al., 2010), was applied to identify RFP+ cells throughout glioma growth. The 
confocal imaging showed that the RFP+ cells were negative for PDGFR-β in the 
Nes-7 days group. These RFP expressing cells colocalized with PDGFR-β+ cells in 
the Nes-21 days group, indicating the RFP+ cells differentiated to mature pericytes 
and expressed pericyte markers during glioma growth (Fig. 4.3.2.1).  
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Figure 4.3.2.1 Immunofluorescence detection of RFP and PDGFR-β expression in the tumor area of animals 
from the Nes-7 days and the Nes-21 days group. Confocal fluorescence images showed the expression of RFP 
(red) and PDGFR-β (Green) in the tumor area of mice from the Nes-7 days and the Nes-21 days group. Scale bars 
are 50 μm in overview-pictures, and 20 μm in orthogonal view (crosshairs). 
According to my analysis, the number of RFP/PDGFR-β double positive cells in the 
tumor area was significantly increased from 4.0 ± 0.88 in the Nes-7 days group to 
9.35±3.08 in the Nes-14 days group (p < 0.0001) and 24.28 ± 5.61 in the Nes-21 days 
group (p < 0.0001) (Fig. 4.3.2.2-A). The percentage of RFP/PDGFR-β double positive 
cells accounting for all RFP+ cells showed a steep increase from 7 days (27.05% ± 
4.31) to 21 days (79.14% ± 9.17) after tumor cells inoculation (p < 0.0001, Fig. 
4.3.2.2-B). The percentage of double positive cells accounting for all PDGFR-β+ cells 
increased from 9.49% ± 1.93 in the Nes-7 days group to 31.06% ± 9.01 in the Nes-21 
days group (p < 0.0001, Fig. 4.3.2.2-C).  
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Figure 4.3.2.2 Quantification of the number of RFP+, PDGFR-β+, and RFP/ PDGFR-β double positive cells 
in the tumor area of Nes-CreERT2+/+;Td-Tomato glioma mice. A) The number of RFP+, PDGFR-β+ and RFP/ 
PDGFR-β double+ cells in Nes-7 (n = 6), Nes-14 (n = 8), and Nes-21 days (n = 8) groups. The percentage of RFP/ 
PDGFR-β double+ cells accounting for all RFP+ cells (B) and all PDGFR-β+ cells (C) between three experimental 
groups. Data are represented as mean ± SEM (****p < 0.0001). 
In the peritumoral area, the number of RFP+ and RFP/PDGFR-β double+ cells 
increased during tumor progression. However, the number of single PDGFR-β + cells 
increased from 20.66 ± 4.39 in the Nes-7 days group to 38.86 ± 11.13 in the Nes-14 
days group; then the number declined to 31.96 ± 7.01 in the Nes-21 days group (Fig. 
4.3.2.3-A). Furthermore, the proportion of RFP+/PDGFR-β double positive cells 
accounting for all RFP+ cells also showed a decline in the Nes-21 days group (6.02 ± 
4.91), even lower than the Nes-7 days group (7.53 ± 5.31) (Fig. 4.3.2.3-B), while no 
difference was observed in the proportion of RFP/PDGFR-β double+ cells accounting 
for all PDGFR-β+ cells (Fig. 4.3.2.3-C). In my previous results, the number of 
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PDGFR-β+ cells significantly increased in the tumor area during glioma progression. 
However, in the peritumoral area, the number of RFP+ and PDGFR-β+ cells declined 
with tumor growth. It is possible that PDGFR-β+ cells from the peritumoral area 
migrate to the tumor area to support tumor growth. This hypothesis needs to be 
addressed in future studies. No significant difference was observed in the percentage 
of RFP+/PDGFR-β+ cells accounting for all PDGFR-β+ cells in the Nes-7, Nes-14, 
and Nes-21 days groups.  
 
Figure 4.3.2.3 Quantification of the number of RFP+, PDGFR-β+, and RFP/ PDGFR-β double positive cells 
in the peritumoral area of Nes-CreERT2+/+;Td-Tomato glioma mice. A) The number of RFP+, PDGFR-β+ and 
RFP/ PDGFR-β double+ cells in the Nes-7 (n = 6), Nes-14 (n = 8), and Nes-21 days groups (n = 8). The 
percentage of RFP/ PDGFR-β double+ cells accounting for all RFP+ cells (B) and all PDGFR-β+ cells (C) 
between three experimental groups. Data are represented as mean ± SEM (*p < 0.05, ****p < 0.0001, ns no 
significant). 
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In the contralateral hemisphere, no differences were observed in the number of 
positive cells or the percentages of RFP/PDGFR-β double+ cells in the Nes-7, Nes-14, 
and Nes-21 days groups (Fig. 4.3.2.4). This suggests that RFP+ or PDGFR-β+ cells in 
the contralateral tumor-free brain hemisphere were not influenced by tumor 
progression.    
 
Figure 4.3.2.4 Quantification of the number of RFP+, PDGFR-β+, and RFP/ PDGFR-Β double positive cells 
in the contralateral tumor-free brain hemisphere of Nes-CreERT2+/+;Td-Tomato glioma mice. A) The number 
of RFP+, PDGFR-β+ and RFP/ PDGFR-β double+ cells in Nes-7 (n = 6), Nes-14 (n = 8), and Nes-21 days groups 
(n = 8). The percentage of RFP/ PDGFR-β double+ cells accounting for all RFP+ cells (B) and all PDGFR-β+ 
cells (C) between three experimental groups. Data are represented as mean ± SEM (*p < 0.05, ****p < 0.0001, ns 
no significant). 
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4.4 Lineage-tracing and cell-type identification using multiple pericyte markers 
Several markers are commonly applied to identify pericytes, including Desmin, 
PDGFR-Β, CD146, and NG2 (Armulik et al., 2011). Therefore, we performed 
combined staining with Desmin, PDGFR-β, CD146, and NG2 all together observed in 
one immunofluorescence channel to directly investigate the relationship between the 
cell lineage of RFP+ cells with pericytes. The confocal imaging showed that very few 
RFP+ cells expressed pericyte markers in the Nes-7 days group; while RFP+ cells 
were abundantly co-localized with pericyte marker-labelling cells in the Nes-21 days 
group (Fig. 4.4-A). The quantification showed that the number of RFP and 
Desmin-/PDGFR-β-/CD146-/NG2- positive cells significantly increased from 3.63 ± 
1.49 in the Nes-7 days group to 26.18 ± 4.55 in the Nes-21 days group (p < 0.05). In 
addition, we found that the majority of RFP+ cells (75%) are negative for mature 
pericyte markers, including Desmin, PDGFR-β, NG2, CD146 at 7 days after the 
tumor inoculation, but most of RFP+ cells (88.10%) acquired mature pericyte markers 
becoming RFP positive, and Desmin-, PGGFR-β-, NG2-, or CD146 positive cells at 
21 days after tumor injection (Fig. 4.4-B). Previous studies have shown that mature 
pericytes express pericyte markers (Bergers and Song, 2005, Winkler et al., 2010). 
The present study has shown that the newly generated RFP+ pericytes are derived 
from RFP+ pericyte progenitor cells (PPCs), which are RFP positive and 
Desmin-/PDGFR-β/NG2-/CD146-negative cells. These results suggest that these 
PPCs differentiate into mature pericytes during glioma progression. 
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Figure 4.4. Combinatorial Immunofluorescence labelling for established pericyte markers (PDGFR-B, 
Desmin, NG2 and CD146; simultaneously detected in the green channel) to investigate if RFP+ cells 
differentiate to pericytes during tumor growth. A) RFP+ cells in the tumor-core are not pericytes in early 
gliomagenesis (7 days after orthotropic glioma implantation), but are pericytes in the fully established tumor (21 
days; a quantification for these immunofluorescence data is shown); note that RFP+ cells represent a very large 
fraction of all intratumoral pericytes. B) Quantification of the percentage of RFP+ cells with positive pericyte 
markers accounting for all RFP+ cells. Data are represented as mean ± SEM (**** p < 0.0001). Scale bars are 50 
μm in overview-pictures, and 20 μm in orthogonal view (crosshairs) 
4.5 Pericyte progenitor-like cells are not derived from the bone marrow 
Previous reports suggested that the bone marrow contributes pericytes to the glioma 
vasculature (Song et al., 2005). In the present study, lineage-tracing experiments in 
different bone marrow chimeric glioma models were applied to determine whether the 
RFP+ PPCs are derived from the bone marrow during tumor development. In the 
BM/Nes-Td-Tomato group, C57B1/6 wild type mice were reconstituted with bone 
marrow donor cells from the Nes-CreERT2+/+;Td-Tomato transgenic strain; while, in 
the BM/PU1-GFP group, Nes-CreERT2+/+;Td-Tomato transgenic mice were 
reconstituted with bone marrow from myeloid-reporter mice (PU.1-GFP mouse strain). 
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In the BM/PU1-GFP group, we found many PU1-GFP+ cells in the tumor area, 
indicating that bone marrow-derived myeloid cells could go through the BBB into the 
brain as expected (Fig.4.5.1-A) (Harrison-Brown et al., 2016). If the RFP+ cells are 
generated from bone marrow-derived cells, the Nes-Cre-RFP donor cells in the 
C57B1/6 wild type mouse model should also infiltrate to the tumor area. However, in 
the BM/Nes-Td-Tomato group, I did not detect RFP+ cells in the tumor area, 
suggesting RFP+ donor cells are not contributed by the bone morrow (Fig4.5.1-B). 
 
Figure 4.5.1. The bone marrow derived donor cells infiltrate to the tumor area. To investigate if RFP+ 
pericytes in our glioma model are bone-derived we created different bone-marrow chimera. A) We used 
Nes-CreERT2+/+;Td-Tomato mice reconstituted with bone marrow from myeloid-reporter mice (PU.1-GFP mouse 
strain) and found that RFP+ cells still develop into pericytes (14 days after glioma-induction); the efficiency of 
bone-marrow-reconstitution is corroborated by the large number of GFP+ cells accumulating in experimental 
gliomas. B) Wild-type mice were reconstituted with bone marrow from the Nes-CreERT2+/+;Td-Tomato 
transgenic strain, 14 days after orthotropic glioma-inoculation no intratumoral RFP+ are visible. C) Quantification 
of data from figures (A) and (B); data are represented as mean ± SEM (**** p < 0.0001). Scale bars are 200 μm.  
To investigated the cell type of the tumor-infiltrating bone marrow-derived cells in 
the BM/PU1-GFP group, we performed immunostaining for Iba1 to label microglia or 
macrophages. The fluorescence images showed that most of the intratumoral 
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PU1-GFP+ (green) cells also express the microglia/macrophage marker (Iba1) in the 
BM/PU1-GFP group. These results confirm that most bone marrow-derived 
PU1-GFP+ cells are microglia or macrophages. 
 
Figure 4.5.2. Immunofluorescence detection of PU1-GFP and iba1 expression in the tumor-core of the 
BM/PU1-GFP group at 14 days after tumor inoculation; note that RFP+ cells colocalize with iba1+ cells. Scale 
bars are 200 μm. 
 
Because irradiation could influence RFP expression in Nes-CreERT2+/+;Td-Tomato 
mice, we further analyzed RFP expression between the Nes-14 days group (without 
lethal irradiation) and the BM/PU1-GFP group (with lethal irradiation). We found that 
RFP expression significantly increased in the BM/PU1-GFP group as compared with 
the Nes-14 days group (Fig. 4.5.3-A). The number of RFP+ cells in the BM/PU1-GFP 
group was 27.8 ± 4.4 in the tumor area, 17.5 ± 2.62 in the peritumoral area, and 13.6 
± 2.65 in the contralateral tumor-free brain hemisphere, compared with 21.55 ± 3.45 
in the tumor area, 8.57 ± 2.29 in the peritumoral area, and 4.12 ± 1.45 in the 
contralateral area of mice from the Nes-14 days group (Fig. 4.5.3-B). Altogether, 
these results indicated that the irradiation does not have a large effect on the number 
iBa1 PU1-GFP Merge
40x magnification
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of recombined cells in the tumor, but can strongly increase the number of RFP+ cells 
in the peritumoral area and in the tumor-free brain. 
 
Figure 4.5.3. The number of RFP expressing cells in BM/PU1-GFP and Nes-14 days groups in the tumor, 
peritumoral area, and contralateral tumor-free brain hemisphere. A) Fluorescence imaging of RFP 
expression in the BM/PU1-GFP and the Nes-14 days group in the tumor, peritumoral, and contralateral areas (20x 
magnification). B) Quantification of the number of RFP+ cells in the tumor, peritumoral, contralateral areas (n = 
12 random fields per mouse) in BM/PU1-GFP and Nes-14 days groups. Data are represented as mean ± SEM (**p 
< 0.01, **** p < 0.0001). Scale bar is 200 μm. 
Moreover, we quantified the number of PDGFR-β+ cells in the Nes-14 days group 
and the BM/PU1-GFP group. In Fig. 4.5.4-A, it is clear that fewer cells stained for 
PDGFR-β in the BM/PU1-GFP group as compared with the Nes-14 days group. The 
number of PDGFR-β+ cells was 26.0 ± 5.51 in the BM/PU1-GFP group and 57.42 ± 
7.44 in the Nes-14 days group (p < 0.00001), as shown in Fig. 4.5.4-B. These results 
showed that there are more RFP+ pericyte progenitors, but less pericyte 
differentiation in the mouse brain after irradiation.  
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Figure 4.5.4. The PDGFR-β expression in the tumor area in BM/PU1-GFP and the Nes-14 days groups. A) 
fluorescence imaging of PDGFR-β expression in the BM/PU1-GFP group and the Nes-14 days group (20x 
magnification). B) Quantification of the number of RFP+ cells in the tumor area (n = 12 random fields per mouse) 
between the BM/PU1-GFP group and the Nes-14 days group. Data are represented as mean ± SEM (**** p < 
0.0001). Scale bar is 200 μm. 
4.6 Ablation of pericyte progenitor like cells reduces tumor size, tumor 
angiogenesis, and the number of pericytes        
In order to investigate the role of PPCs during tumor progression, I applied a lineage 
ablation glioma mouse model to kill the Cre recombined RFP+ cells. Because our 
previous results (Figure 4.4) showed that most RFP positive cells are PPCs at the 
early stage of tumor development, we performed TAM injection to ablate recombined 
RFP+ cells at 4 days after tumor inoculation. RFP expression was compared in 
transgenic models with (the Nes-iDTA group) and without (the Nes-RFP group) 
iDTA cell-lineage ablation (Fig 4.6.1-A, groups define shown in Table 3.1). The 
number of RFP+ cells significantly decreased in the Nes-iDTA group (10.29 ± 4.77) 
as compared with the Nes-RFP group (20.61 ± 4.09, p < 0.0001) in the tumor area. 
After TAM administration in the Nes-iDTA group, the number of RFP+ cells was 
reduced by approximately 50% in the tumor area. These results indicated that we 
successfully established a mouse model to ablate the RFP+ PPCs.  
RESULTS 
 57 
 
Figure 4.6.1. The number of RFP expressing cells between the Nes-iDTA group and the Nes-RFP group. A) 
Fluorescence imaging of the RFP expression between the Nes-iDTA group and Nes-RFP group in the tumor, 
peritumoral, and contralateral areas. B) Quantification of the number of RFP+ cells in the tumor, peritumoral, and 
contralateral areas (n = 12 random fields per mouse) in two experimental groups. Data are represented as mean ± 
SEM (*p < 0.05, *** p < 0.0005). Scale bar is 200 μm. 
We performed a H&E staining to investigate the tumor volumes in the Nes-iDTA 
group and the Nes-RFP group. I found that tumor volumes were smaller in the 
Nes-iDTA group as compared with the Nes-RFP group, as shown in Fig 4.6.2-A. The 
quantification showed a significant decrease of tumor volumes in the Nes-iDTA 
group as compared with the Nes-RFP control group (4.75 mm3 ± 2.25 versus 8.55 
mm3 ± 2.36; p = 0.0357; Fig. 4.6.2-B). The tumor volume was reduced by 45%, when 
we ablated RFP+ PPCs.  
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Figure 4.6.2. Tumor volumes were decreased after ablating the RFP+ PPCs. Tumor volume was compared in 
transgenic models with (Nes-iDTA) and without (Nes-RFP) -iDTA cell-lineage ablation. Animals were treated as 
the Nes-14 days group, which assures that preponderantly pericyte-progenitors are ablated in the Nes-iDTA model 
and that a large tumor mass is formed. A) Illustrates tumor morphology by H&E staining in both experimental 
groups. B) Quantification of the tumor volume (mm3) in both groups; note that pericyte progenitor ablation largely 
reduces tumor volume, data are represented as mean ± SEM (*p < 0.05). Scale bars are 200 μm in 1.25x and 5x 
magnification; 100 μm in 10x magnification.   
To investigate tumor angiogenesis in our glioma mouse model after ablation of RFP+ 
cells, a vWF staining was performed. The illustrated fluorescence images show the 
number of vWF expressing cells significantly decreased in the Nes-iDTA group as 
compared with the Nes-RFP control group (Fig 4.6.3-A). The total blood vessel 
covered area significantly declined in the Nes-iDTA group as compared with the 
Nes-RFP group (7.67% ± 1.88 versus 11.69% ± 3.20; p < 0.0001, Fig. 4.6.3-B). When 
we ablated the RFP+ PPCs, the vessel area was reduced by 50% as compared to the 
Nes-RFP group. In addition, a significant reduction in vessel density (p = 0.0002) and 
vessel network complexity (p = 0.0096) was observed in the Nes-iDTA group as 
compared with the Nes-RFP group. 
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Figure 4.6.3. Ablation of pericyte progenitors is anti-angiogenic. A) Immunofluorescence detection of vWF in 
the entire tumor are (of representative horizontal cross-section); note that Vascular density and complexity are 
largely reduced in Nes-iDTA mice as compared to the Nes-RFP model. Quantification of vessel covered area (B), 
vessel density (C), and vessel network complexity (D) in both experimental groups. Data are represented as mean 
± SEM (**p < 0.01, ***p < 0.005, **** p < 0.0001, nsno significant). Scale bars are 200 μm. 
We further investigated PDGFR-β expression after RFP+ cell ablation. In Fig 4.6.4-A, 
in the tumor area, the number of RFP+, PDGFR-β+, and double positive cells 
significantly decreased in the Nes-iDTA group as compared with the Nes-RFP group. 
The quantification showed a significant reduction in the Nes-iDTA group as 
compared with the Nes-RFP group, in terms of the number of PDGFR-β+ (41.17 ± 
8.99 versus 57.42 ± 7.44, p < 0.05) and PDGFR-β/RFP double positive cells (3.75 ± 
1.56 versus 9.35 ± 3.08, p < 0.05), as shown in Fig. 4.6.4-B. The percentage of 
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PDGFR-β/RFP double positive cells accounting for all RFP+ cells showed a sharp 
reduction in the Nes-iDTA group (37.88% ± 4.31) as compared with the Nes-RFP 
group (54.69% ± 12.86, p < 0.05) (Fig. 4.6.4-C). A significant reduction was observed 
in the percentage of PDGFR-β/RFP double positive cells accounting for all 
PDGFR-β+ cells between two experimental groups (9.18% ± 5.58 versus 18.47% ± 
5.63, p < 0.05) (Fig. 4.6.4-D). 
 
Figure 4.6.4 Immunofluorescence detection and quantification of PDGFR-β expressing cells in the tumor 
area between the Nes-iDTA group and the Nes-RFP group. A) Representative fluorescence images showed the 
expression of RFP (red) and PDGFR-β (green) between the Nes-iDTA group and the Nes-RFP group. The 
quantification of (B) PDGFR-β+, and RFP/PDGFR-β double+ cells (n = 12 random fields per mouse), (C) the 
percentage of RFP/PDGFR-β double+ accounting for all RFP+ cells and (D) for all PDGFR-β+ cells in both 
experimental groups. Data are represented as mean ± SEM (**p < 0.01, ***p < 0.005, ****p < 0.0001). Scale bar 
is 200 μm.
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5 DISCUSSION 
Pericytes are mural cells that contribute to vessel function and formation in both 
healthy (Garmy-Susini and Varner, 2005, Crisan et al., 2008, Armulik et al., 2010) 
and pathological tissues (Enge et al., 2002, Xian et al., 2006, Nishimura et al., 2016, 
Paez-Ribes et al., 2009, Paquet-Fifield et al., 2009). In the CNS, pericytes play an 
important role in establishing and maintaining the BBB and angiogenesis, together 
with endothelial cells, astrocytes, and neurons (Halliday et al., 2016, Caporali et al., 
2016, Dumpich and Theiss, 2015). Moreover, using pericyte deficient mouse model, it 
has been proven previously that pericytes are involved in brain tumor progression and 
expansion (Youn et al., 2015, Yotsumoto et al., 2015). Several markers were applied 
to identify mature pericytes, including PDGFR-β, Desmin, NG2, CD146, Rgs5, etc 
(Armulik et al., 2011, Mitchell et al., 2008). However, none of these markers alone is 
fully sufficient to unequivocally identify pericytes. The current definition of a pericyte 
is based on a combination of morphological patterns and the expression of at least two 
pericyte markers (Armulik et al., 2011, Trost et al., 2016). It is the currant view in the 
field of vascular research that pericytes in the brain are derived from the neuronal 
crest and that developmentally generated mature pericytes can proliferate to provide 
more pericytes during neoangiogenesis in the postnatal brain (Viski et al., 2016, 
Simonavicius et al., 2012).   
In the present study, applying transgenic lineage-racing and bone marrow chimeric 
glioma mouse models, we investigate the cell linage, origination, and abolition of 
pericyte progenitor cells within tumor progression. The principle findings of this 
study are as follows, 1) we found that a group of RFP positive cells does not express 
any pericyte markers in the early stages after tumor inoculation. While, in later stages 
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of tumorigenesis, most of the RFP+ cells differentiated into mature pericytes express 
pericyte markers. It is concluded from this study that the RFP+ and pericyte-marker 
negative cells are a pericyte progenitor (PPC), which is dormant without a demand for 
new vessels and become activated during angiogenesis; 2) In the tumor area, most of 
the newly generated pericytes (63.14%) are derived from PPCs; while RFP positive 
PPCs do not differentiate in the peritumoral and the contralateral tumor-free brain 
hemisphere; 3) The bone marrow chimeric experiment confirmed that PPCs are not 
derived from the bone marrow; Moreover, 4) Results from lineage ablation 
experiments showed that the ablation of RFP positive PPCs could reduce the tumor 
size, tumor angiogenesis, and the number of pericytes. Consequently, these findings 
suggested that RFP positive PPCs contribute a potential new therapeutic target to 
suppress the tumor progression. 
5.1 Identification of the RFP+ pericyte progenitor-like cells  
To delineate the cell linage of RFP+ cells, we performed in vivo experiments with the 
NesCreERT2+/+;Td-Tomato mouse model. With tumor progression, the number of RFP 
expressing cells significantly increased in the tumor, the peritumoral, and the 
contralateral tumor-free hemisphere. At 21 days after tumor cell-inoculation, I found 
that most RFP+ cells present a vessel-like morphology and located nearby to the 
vessels. In addition, RFP positive cells have a somewhat reduced capacity to generate 
new progenies with advanced age. 
Based on the localization and characterization of RFP expressing cells, we further 
performed immunofluorescence staining for VWF, Desmin, and PDGFR-β to 
characterize RFP+ PPCs. According to the confocal imaging, RFP+ cells were located 
close to VWF+ cells, and co-localized with Desmin+ or PDGFR-β+ cells at 21 days 
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after tumor inoculation. The quantification showed a significant increase in the 
number of pericytes in the tumor area of the Nes-21 days group as compared with the 
Nes-7 days group.  
Considering that in blood vessels Desmin and PDGFR-β are only expressed in the 
mature pericyte, our findings indicated that the RFP/Desmin or RFP/PDGFR-β double 
positive cells are pericytes. The quantitative analysis showed that the number of 
RFP/Desmin or RFP/PDGFR-β double positive cells significantly increased during 
tumor progression. The proportion of these double positive cells was initially 
approximately 23.23% in RFP/Desmin double + cells and 27.01% in RFP/PDGFR-β 
double + cells of all RFP+ cells at 7 days after the tumor inoculation, then increased 
to 71.98% and 79.13% at 21 days. In the Nes-21 days group, RFP+ pericytes 
accounted for approximately one third of all mature pericytes in the tumor area. In 
addition, using multiple pericyte markers staining, we identified most of intratumoral 
RFP+ cells (75.04%) were negative for mature pericytes markers (Desmin, PDGFR-β, 
CD146, and NG2) at 7 days after the tumor inoculation. Then, approximately 88.10% 
of RFP+ cells expressed the pericyte markers at 21 days after tumor cell-inoculation. 
Present study suggests that pericytes marker negative RFP+ cells could be previously 
unrecognized PPCs, which mature into pericytes during glioma progression. In the 
tumor area, we found most of newly generated pericytes (63.14%) are RFP expressing 
cells.  
This study demonstrated that the number of RFP+ cell significantly increased in the 
peritumoral and the contralateral area during glioma progression. However, we also 
found that no significant difference was observed in the number of RFP/Desmin or 
PDGFR-β double positive cells in the peritumoral and contralateral areas. Therefore, 
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we suggested that RFP+ PPCs only differentiated in the tumor area, rather than in the 
peritumoral area and the contralateral tumor-free hemisphere.  
5.2 RFP positive pericyte progenitor like cells are not derived from bone marrow 
Despite an increasing interest in the role of pericytes in brain tumor growth, the 
precise origination of brain pericyte remains poorly understood. Previous studies have 
identified several sources of pericytes in different tissues and organs. In heart tissue, 
several studies have shown that PDGFR-β positive mural progenitor cells are derived 
from the embryonic epicardium cells and differentiate into pericytes (Avolio and 
Madeddu, 2016, Chen et al., 2016). Chen et al. indicated that the endocardial 
endothelial cells in the murine embryonic heart are progenitors of coronary pericytes, 
which are relevant to heart function and diseases (Chen et al., 2016). In 2016, a new 
experiment demonstrated that the Procr+ (protein c receptor-expressing) endothelial 
cells are an additional local source of pericytes (Yu et al., 2016).  
In the healthy and diseased brain, previous studies have proven that pericytes could 
originate from the glioma stem cells, mesenchymal stem cells, or bone marrow 
derived cells (Ricci-Vitiani et al., 2010, Lamagna and Bergers, 2006, Song et al., 2005, 
Bababeygy et al., 2008, Bexell et al., 2009). In the present research, the bone marrow 
chimeric mouse model was applied to further investigate the origination of the RFP+ 
pericyte progenitor cells. In the BM/PU1-GFP group, PU1-GFP+ cells were observed 
in the tumor area, indicating that bone marrow derived myeloid cells could migrate to 
the tumor area through the BBB. If RFP+ PPCs were derived from the bone marrow, I 
have been able to detect RFP+ cells in the tumor area of the BM/Nes-Td-Tomato 
group. However, I found no RFP+ cells infiltrating into the brain tumor area in this 
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model. Therefore, this study concluded that RFP+ PPCs are not generated from bone 
marrow derived cells. 
In addition, we found that most intratumoral PU1-GFP+ cells are co-localized with 
the immunofluorescence labeling for Iba1+ cells in the BM/PU1-GFP group. The 
results demonstrated that most of infiltrated bone marrow derived PU1-GFP+ cells 
are microglia or macrophages. 
5.3 The RFP+ pericyte progenitor like cells as a new therapeutic target for 
glioma 
Malignant gliomas are characterized by microvascular proliferation and typically 
over-expresses vascular endothelial growth factor (VEGF), which promotes tumor 
angiogenesis, proliferation, and progression (Kargiotis et al., 2006, Jain et al., 2007, 
Fischer et al., 2005). In the past two decades, the endothelial cells were widely 
considered to be the main therapeutic target for anti-angiogenesis (Dumpich and 
Theiss, 2015, Beal et al., 2011). Bevacizumab (BV), a humanized monoclonal 
antibody for VEGF, has been approved by The U.S. Food and Drug Administration 
(FDA) for second-line treatment of recurrent GBM (Kreisl et al., 2009, Friedman et 
al., 2009). Several clinical trials have reported that treatment with combinations of 
BV and other therapeutic agents (temozolomide, sunitinib, carboplatin, ect.) results in 
stable responses and a prolonged 6-month progression-free survival (PFS) rate in 
patients with recurrent high-grade glioma, but do not significantly prolong overall 
survival (OS) (Gil et al., 2012, Moller et al., 2012, Paldino et al., 2012, Jakobsen et al., 
2011, Duda et al., 2007, Bennett et al., 2017). Furthermore, most of the complications 
caused by the toxicity of the combined chemotherapy led to discontinuation of 
treatment for patients with glioma (Ballman et al., 2007). Recently, we performed a 
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meta-analysis to investigate the effect of bevacizumab for newly diagnosed glioma 
(Li et al., 2016). The results showed that bevacizumab did not improve the median 
overall survival but resulted in longer median PFS. Additionally, the long-term use of 
BV is associated with a higher incidence of adverse events and mortality. Some 
studies indicated that the long-term bevacizumab application could lead to drug 
resistance. Although anti-VEGF therapy could inhibit the VEGF–VEGFR signal 
pathway to suppress tumor growth and reduce cerebral oxygen delivery, the 
expression of hypoxia-inducible factor 1alpha (HIF-1 α) was up-regulated to further 
promote the expression of VEGF genes (Hormigo et al., 2011, Mizukami et al., 2005). 
Placental growth factor (PGF), a member of the VEGF sub-family, could also 
promote the proliferation and migration of endothelial cells. After inhibiting VEGF, 
endothelial cells could up-regulate the expression of PGF to maintain 
tumor-associated vascular growth (Fischer et al., 2007), which may represent on 
reason why the anti-VEGF therapies did not show benefits for patients with glioma. 
Recently, more research has been focused on pericytes, another type of cell in the 
perivascular area. The aims of pericyte-targeted therapy are to maintain the 
normalization of tumor vascularization to increase tumor oxygenation and 
intracerebral blood flow. Several studies investigated the effect of different kinds of 
anti-pericyte therapies for tumorigenesis, including targeting pericyte overexpressed 
markers (Xian et al., 2006), signal pathway inhibitor 3 (Bergers et al., 2003), blocking 
PDGFR-β (Cooke et al., 2012, Song et al., 2005), and PDGF-B–PDGFR-β binding 
oligonucleotide aptamers (Sennino et al., 2007). The application of the anti-PDGFR-β 
antibody could deplete pericytes in the pancreatic cancer mouse model leading to 
enlargement of the tumor vessels and promotion of the apoptosis of endothelial cells 
(Song et al., 2005). These studies suggested that the anti-pericyte therapies could 
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reduce the pericyte coverage, vascular stabilization, and tumor volume. However, low 
pericyte coverage and vascular destabilization could promote tumor hypoxia, necrosis, 
and metastasis (Bergers et al., 2003, Xian et al., 2006). A study conducted by Sinha et 
al. indicated that low pericyte coverage was relevant to rapid progress and mortality 
of patients with ovarian cancer (Sinha et al., 2016). Some clinical trials also indicated 
that low pericyte coverage is associated with poor prognosis in patients with 
glioblastoma (Yonenaga et al., 2005, O'Keeffe et al., 2008). Considering that the 
co-targeting of endothelia and pericytes might be much more effective for 
glioblastoma, two phase-II clinical studies investigated the effect of nintedanib (a 
triple tyrosine kinase receptor inhibitor of PDGFR-α/β, FGFR 1/3, and VEGFR 1-3) 
for patients with recurrent high-grade gliomas (Norden et al., 2015, Muhic et al., 
2013). However, these two clinical trials suggested that nintedanib does not show 
benefit for patients with glioma, and the reason for the poor outcomes in nintedanib 
group is still unclear.  
In our study, we used the cell-lineage ablation glioma mouse model to investigate the 
role of PPCs during glioma progression. The ablation of recombined RFP positive 
cells was applied at the early stage of tumor development where most RFP+ cells are 
PPCs (negative for pericytes markers). We ablated approximately half of the lineage 
traced cells in the Nes-iDTA group, as compared to the Nes-14 days group. Ablation 
of RFP positive PPCs significantly reduced the tumor volume by 46%, vessel area 
coverage by 50%, vessel density 64%, and vessel network complexity by 56% in the 
Nes-iDTA group as compared with the WT-iDTA control group. Hence, we 
suggested that the RFP+ PPCs may support the glioma progression and tumor 
angiogenesis.   
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Birbrair et al. reported that type-2 pericytes (nestin+/NG2+) promoted tumor 
angiogenesis, which may provide a potential target for inhibiting malignant tumors.  
(Birbrair et al., 2014). In this study, I used cell lineage transgenic mouse model to 
trace PPCs during tumor growth, my results showed that PPCs are nestin positive but 
NG2 negative immature pericytes that promote tumor angiogenesis. During glioma 
progression, PPCs could differentiate into mature pericytes (expressing NG2) 
becoming type-2 pericytes. Therefore, the role of different type of pericytes during 
tumor angiogenesis remains to be clarified. 
Unlike targeting PDGFR-β or NG2 to ablate pericytes or other cell types, we ablated 
RFP+ PPCs in the glioma-bearing mouse brain. Our study demonstrated that the 
RFP+ PPCs are only differentiated in the tumor area, rather than in the peritumoral 
area and the tumor-free hemisphere. In addition, I confirmed that PPCs are not 
derived from the bone marrow. Therefore, ablation of PPCs could avoid 
complications associated with excluding mature pericytes in the brain or other organs. 
Altogether our data indicate that the RFP+ PPCs contribute important roles in glioma 
progression and angiogenesis. Therefore, these newly-identified PPCs could be 
considered as a new therapeutic target for glioma.  
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6 SUMMARY 
Pericytes are vascular mural cell, which can regulate vessel-tone and -remodeling. In 
the brain pericytes are maintained in a 1:1 ratio with endothelial cells, they are 
essential for the function of the blood-brain barrier and control vessel-architecture. 
Previous studies suggested that pericytes are generated in embryonic development 
and that mature pericytes would proliferate and expand during neo-angiogenesis. 
Furthermore, it was proposed that pathological angiogenesis in glioblastomas (GBM) 
is supported by bone marrow-derived pericytes. In the present study, applying newly 
established transgenic lineage-tracing glioma mouse models (Nes-CreERT2; 
Td-Tomato), I newly observed that pericytes origin from a previously unknown 
pericyte progenitor cells (PPCs). These nesting-RFP positive PPCs are negative for 
mature pericyte markers, including Desmin, PDGFR-β, NG2, CD146 at 7 days after 
tumor inoculation. However, most PPCs (88.10%) developed into mature pericytes 
and expressed pericyte markers like Desmin, PGGFR-ß, NG2, or CD146 at 21 days 
after tumor injection. I suggested that pericytes marker negative RFP+ cells are a 
previously unrecognized PPCs. Interestingly, in the tumor area, more than 30% of all 
pericytes express RFP. Since we used cell lineage tracing mouse models, we indicated 
that these intratumoral newly generated mature pericytes are derived from PPCs. The 
RFP positive cells do not differentiate into mature pericyte in the peritumoral and the 
contralateral tumor-free brain hemisphere.  
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The bone marrow chimeric glioma mouse model was applied to investigate if RFP 
expressing cells derived from the brain or from bone marrow. In the BM/PU1-GFP 
mice, we confirm that bone marrow derived PU1-GFP+ myeloid cells could migrate 
to the tumor area through the BBB. However, in the BM/Nes-Td-Tomato group, no 
RFP expressing cells are detected in glioma. These findings indicated that PPCs are 
not generated from bone marrow derived cells.  
In the final experiments of my thesis, a cell lineage ablation glioma mouse model was 
used to investigate the role of PPCs during glioma growth. The ablation of Cre 
recombined RFP + cells was applied at 4 days after tumor inoculation, due to most 
RFP positive cells are PPCs during this stage. The results showed that we ablate 
approximately half of the RFP+ cells in the Nes-iDTA group compared to the 
Nes-RFP group. After ablation of RFP+ cells in the Nes-iDTA group, we observed 
significant reductions in the tumor volume, tumor angiogenesis, and the number of 
pericytes as compared with the Nes-RFP group. This study suggests that the RFP+ 
PPCs contribute important roles in glioma progression and angiogenesis. Altogether 
our data hypothesize that pericyte progenitor cells are a new target for 
anti-angiogenesis in GBM, which will allow a specific and efficient therapeutic 
treatment. 
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APPENDIX 
ABBREVIATIONS 
Ang/Tie2 Angiopoietin-1/2 and Tie2  
αSMA α-smooth muscle actin 
BBB Blood brain barrier 
bFGF Basic fibroblasts growth factor 
BM Basement membrane 
CNS  Central nervous system 
CldU Chlorodeoxyuridine 
CSC Cancer stem cell 
d                                Day 
DAPI                            4,6-diamidino-2-phenylindole 
EC Endothelial cells 
FFPE Formalin-fixed, paraffin-embedded  
Fig.                Figure 
GAPDH  Glyceraldehyde-3- phosphate dehydrogenase 
GBM            Glioblastoma multiforme 
GFP            Green fluorescent protein 
GL261       Murine high-grade astrocytoma cell line 
iDTA Cre-inducible diphtheria toxin a 
IdU Iododeoxyuridine 
IDH isocitrate dehydrogenase 
i.p.               Intraperitoneal 
MGMT O6-methylguanin-DNA-methyltransferase 
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MSC Mesenchymal stem cell 
NG2 Nerve/glial antigen 2 proteoglycan 
NVU Neurovascular unit 
o/n             Over night 
PBS             Phosphate buffered saline 
PDGF-B Platelet-derived growth factor subunit B 
PDGFR-β Platelet-derived growth factor receptor β 
PFA               Paraformaldehyde 
PPC Pericyte progenitor like cells 
RFP Red fluorescent protein 
RT Rome temperature 
TAM         Tumor associated macrophage 
TBS          Tris-buffered saline 
TGF-β Transforming growth factor-β 
TMZ Temozolomide 
VEGF Vascular endothelial growth factor 
WHO         World Health Organization 
WT          Wildtype 
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